Short-Course Hypofractionated Radiation Therapy With Boost in Women With Stages 0 to IIIa Breast Cancer: A Phase 2 Trial

• Published in: International journal of radiation oncology, biology, physics Vol. 94; no. 1; pp. 118 - 125
• Main Authors: Ahlawat, Stuti, MD, Haffty, Bruce G., MD, Goyal, Sharad, MD, Kearney, Thomas, MD, Kirstein, Laurie, MD, Chen, Chunxia, MS, Moore, Dirk F., PhD, Khan, Atif J., MD
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 2016
• Subjects: Adult; Aged; Breast Neoplasms - pathology; Breast Neoplasms - radiotherapy; Carcinoma in Situ - pathology; Carcinoma in Situ - radiotherapy; Carcinoma, Ductal, Breast - pathology; Carcinoma, Ductal, Breast - radiotherapy; Carcinoma, Lobular - pathology; Carcinoma, Lobular - radiotherapy; CONSUMER PRODUCTS; Disease-Free Survival; Dose Hypofractionation; Female; Follow-Up Studies; FRACTIONATION; GY RANGE 01-10; GY RANGE 10-100; Hematology, Oncology and Palliative Medicine; Humans; MAMMARY GLANDS; Mastectomy, Segmental; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; NEOPLASMS; PATIENTS; Prospective Studies; Radiation Injuries - pathology; Radiodermatitis - pathology; Radiology; RADIOLOGY AND NUCLEAR MEDICINE; RADIOTHERAPY; Time Factors; TOXICITY; WOMEN

Purpose Conventionally fractionated whole-breast irradiation (WBI) with a boost takes approximately 6 to 7 weeks. We evaluated a short course of hypofractionated (HF), accelerated WBI in which therapy was completed in 3 weeks inclusive of a sequential boost. Methods and Materials We delivered a whol...